メバロチン錠５ ５ｍｇ
基本情報
| 項目 | 値 |
|---|---|
| DrugBank ID | DB00175 |
| エビデンスレベル | L5（計算予測のみ） |
| 予測適応症数 | 53 |
| 日本商品名（例） | プラバスタチンナトリウム錠１０ｍｇ「ツルハラ」, プラバスタチンナトリウム錠１０ｍｇ「ＹＤ」, プラバスタチンナトリウム錠５ｍｇ「ツルハラ」 |
承認適応症（KEGG）
高脂血症、家族性高コレステロール血症
予測適応症（TxGNN）
以下は TxGNN モデルにより予測された潜在的新適応症です。スコアが高いほど関連性が高いと予測されています。
| # | 適応症 | スコア | ソース |
|---|---|---|---|
| 1 | hyperlipoproteinemia | 99% | DL |
| 2 | obsolete familial combined hyperlipidemia | 99% | DL |
| 3 | homozygous familial hypercholesterolemia | 99% | DL |
| 4 | HIV infectious disease | 99% | DL |
| 5 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 99% | DL |
| 6 | simian immunodeficiency virus infection | 99% | DL |
| 7 | feline acquired immunodeficiency syndrome | 99% | DL |
| 8 | familial hypercholesterolemia | 99% | DL |
| 9 | hypoalphalipoproteinemia | 99% | DL |
| 10 | hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency | 99% | DL |
| 11 | cholesterol-ester transfer protein deficiency | 99% | DL |
| 12 | hyperlipidemia, familial combined, LPL related | 98% | DL |
| 13 | obsolete susceptibility to ischemic stroke | 98% | DL |
| 14 | hypercholesterolemia, autosomal dominant | 98% | DL |
| 15 | familial hyperlipidemia | 98% | DL |
| 16 | brain stem infarction | 98% | DL |
| 17 | hyperlipidemia due to hepatic triglyceride lipase deficiency | 98% | DL |
| 18 | hypolipoproteinemia (disease) | 98% | DL |
| 19 | hyperlipidemia | 98% | DL |
| 20 | cerebral infarction | 97% | DL |
| 21 | stroke disorder | 97% | DL |
| 22 | ABri amyloidosis | 97% | DL |
| 23 | fibroma of prostate | 97% | DL |
| 24 | benign reproductive system neoplasm | 96% | DL |
| 25 | cerebral arterial disease | 96% | DL |
| 26 | cerebral artery occlusion | 96% | DL |
| 27 | Brenner tumor | 96% | DL |
| 28 | benign prostate phyllodes tumor | 96% | DL |
| 29 | prostate cancer/brain cancer susceptibility | 96% | DL |
| 30 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | 95% | DL |
| 31 | male reproductive organ cancer | 95% | DL |
| 32 | brain small vessel disease 1 with or without ocular anomalies | 95% | DL |
| 33 | prostate leiomyoma | 95% | DL |
| 34 | intracerebral hemorrhage | 95% | DL |
| 35 | duodenal obstruction | 95% | DL |
| 36 | MRI defined brain infarct | 95% | DL |
| 37 | arteriosclerosis disorder | 93% | DL |
| 38 | chronic kidney disease | 93% | DL |
| 39 | congestive heart failure | 93% | DL |
| 40 | female breast carcinoma | 93% | DL |
| 41 | glaucoma | 93% | DL |
| 42 | duodenal ulcer (disease) | 93% | DL |
| 43 | cerebrovascular disorder | 92% | DL |
| 44 | cerebral atherosclerosis | 92% | DL |
| 45 | generalized atherosclerosis | 92% | DL |
| 46 | hyperalphalipoproteinemia | 92% | DL |
| 47 | ABeta amyloidosis | 91% | DL |
| 48 | duodenogastric reflux | 91% | DL |
| 49 | diabetic nephropathy | 91% | DL |
| 50 | AIDS | 91% | DL |
（上位50件を表示。全53件の予測があります）
免責事項
これらの予測は研究目的のみであり、医療アドバイスを構成するものではありません。 臨床応用には必ず適切な検証が必要です。